Bruce Booth - 14 Dec 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Director
Signature: /s/ Ommer Chohan, Attorney-in-Fact
Issuer symbol: KYMR
Transactions as of: 14 Dec 2022
Net transactions value: -$11,985,954
Form type: 4
Filing time: 16 Dec 2022, 16:05:47 UTC
Previous filing: 04 Nov 2022
Next filing: 13 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Sale	$3,416,159	-112,819	-2.1%	$30.28	5,252,744	14 Dec 2022	See footnote	F1, F2, F3
transaction	KYMR	Common Stock	Sale	$3,181,382	-101,189	-1.9%	$31.44	5,151,555	14 Dec 2022	See footnote	F1, F3, F4
transaction	KYMR	Common Stock	Sale	$1,769,647	-54,737	-1.1%	$32.33	5,096,818	14 Dec 2022	See footnote	F1, F3, F5
transaction	KYMR	Common Stock	Sale	$466,660	-13,997	-0.27%	$33.34	5,082,821	14 Dec 2022	See footnote	F1, F3, F6
transaction	KYMR	Common Stock	Sale	$453,657	-13,335	-0.26%	$34.02	5,069,486	14 Dec 2022	See footnote	F1, F3, F7
transaction	KYMR	Common Stock	Sale	$956,364	-31,584	-3.2%	$30.28	969,833	14 Dec 2022	See footnote	F1, F2, F8
transaction	KYMR	Common Stock	Sale	$890,664	-28,329	-2.9%	$31.44	941,504	14 Dec 2022	See footnote	F1, F4, F8
transaction	KYMR	Common Stock	Sale	$495,425	-15,324	-1.6%	$32.33	926,180	14 Dec 2022	See footnote	F1, F5, F8
transaction	KYMR	Common Stock	Sale	$130,659	-3,919	-0.42%	$33.34	922,261	14 Dec 2022	See footnote	F1, F6, F8
transaction	KYMR	Common Stock	Sale	$126,997	-3,733	-0.4%	$34.02	918,528	14 Dec 2022	See footnote	F1, F7, F8
transaction	KYMR	Common Stock	Sale	$76,830	-2,561	-0.05%	$30.00	5,066,925	15 Dec 2022	See footnote	F1, F3, F9
transaction	KYMR	Common Stock	Sale	$21,510	-717	-0.08%	$30.00	917,811	15 Dec 2022	See footnote	F1, F8, F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were sold pursuant to a Rule 10b5-1 trading plan.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (9).
F3	These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.95 to $31.945 inclusive.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.95 to $32.94 inclusive.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.89 inclusive.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.95 to $34.20 inclusive.
F8	The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
F9	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive.